Genmab — Februar 2025
-
LOL uha det er sgu et dårligt eksempel du lige hiver frem der. Enig det hjælper på sandsynlighed for succes at gen1042 har BNTX med. Jeg tror dog at der ifm med gen1046 learnings eller lige før gen1046 data, var noget der kunne ligne en nulstilling af gen1042 forsøget. De lagde mange nye patienter til, og med det også noget der kunne ligne en ny tidslinje. Men håber da Jan har er troværdig.
-
Jan - So the data we are waiting for is duration, duration of responses, and that takes time. Unfortunately, that takes time. And actually, the more time it takes probably the better it is. But we also want to say that the market is restless, and we also did our partner biontech, because we're both fully invested in that molecule. We're very excited about that molecule, James.
-
So we fully believe that we will continue with working on that molecule -- but we have to evaluate right now. I think I spoke about frontline head and neck cancer because that's where we have most of the data, but we also have data in other cancers.
We think that, that's a fantastic immune activator also to use potentially in combination with ADC. -
And then on top of that, bispecific antibodies like these have bell-shaped curves, so very complex kinetics. So it takes a lot more time than ADC.
So I think the mix is actually quite ideal when you have both access to immuno-oncology molecules and different types of ADCs. You can actually come to combination regimens, which are completely chemo-free and potentially much better treatments -
Tak EL, Lad so håbe Jan har ret ( at DoR er lang) ihverfald at der fra trial start er gået laaang tid. Men jeg ser det ikke udelukkende positivt at han "allerede" snakke kombination med ADC. Lægger han op til en kombi behandling, er effekten for lille ? Kommer effekten for sent ?
-
-
Jan -I mean as per the contract, yes, we can develop the molecule of cells if the J&J would decide not to opt in but not any indications where daratumumab is on the market or where it's in late-stage clinical development. That means other indications in multiple myeloma. There's still some areas left where daratumumab doesn't work or stopped working. We can potentially think about other cancers like AML, diffuse line banner, where we have seen some very good preclinical data with this molecule.
-
Another potential is solid tumors book.
And the reason that I mentioned that, James, is that the antibody, which is part of HexaBody-CD38 is a very good block of the ecto-enzymatic activity of the CD38 molecule, which is involved in the creation of adenosine. Adenosine is an immunosuppressive molecule. So potentially, this antibody is much better immune activator than daratumumab. It could be a key reason to use it in combination with checkpoint targeted molecules based on preclinical data. -
Finally, this could be a molecule which is of important for treatment of I&I or autoimmune diseases and inflammatory diseases because of the that daratumumab is known to be actually pretty active in some of the inflammatory diseases. But this is all speculation, let's first wait on the J&J optinn
decision. -
Q Would you be in a position to say, right, we're really like taking this into clinical development or would it more be we now need to do some very early exploratory trials because you just don't know that much yet about how well it would work, say, outside the DARZALEX indications?
-
Jan You definitely need to look at safety and you probably need a subcutaneous formulation, I think, for many of these indications because what you see the trend is with antibody medicines that more and more of them are formulated formulations and definitely in multiple myeloma that is the situation. But also, of course, in automimmune
diseases. I mean, and that needs to be a next step, I think, once you decide on developing that program.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind